Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
How did MoneyWorks4me help subscribers to buy Divis Lab at Rs. 629/ share in 2017?
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) Stock Analysis

Small Cap
Evaluated by 1561 users | BSE: 532526 | NSE: DISHMAN |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation
 Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
Return on Capital Employed 11.54%10.23%15.51%9.49%6%7.73%8.59%10.43%7.22%8.79%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 275359416353421463485473492510417
Y-o-Y Gr. Rt.-30.5%15.8%-15.2%19.3%10.1%4.6%-2.3%4%3.7%-
Adjusted EPS (Rs.) 3.763.696.334.262.423.174.135.33.285.224.06
Y-o-Y Gr. Rt.--1.9%71.5%-32.7%-43.2%31%30.3%28.3%-38.1%59.2%-
Book Value per Share (Rs.) 18.4628.3234.0237.8439.6341.6344.8449.2851.7256.37295.49
Adjusted Net Profit 54.258.910268.839.151.166.785.65384.266
Net Op. Cash Flow (Rs. Cr.) 21.242.590.811011825028.312614.5125-
Debt to Cash Flow from Ops 14.16.183.23.964.761.9618.484.1843.445.04-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 7.1%3.9%1.7%3.7%
Adjusted EPS 3.7%16.6%8.1%59.2%
Book Value per Share 13.27.37.99
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
Return on Equity (%) 24.6116.2820.2911.796.237.779.5311.246.489.642.31
Operating Profit Margin (%) 25.6925.6336.133.272433.3835.9637.2330.1233.4632.5
Net Profit Margin (%) 19.716.3824.5719.519.2911.0313.7518.0810.7616.515.72
Debt to Equity 1.120.580.530.710.880.730.720.660.760.69-
Working Capital Days 325307270347417436406467564638-
Cash Conversion Cycle 183168133101796153508591-
Loading price chart...
Entity Percentage Holding
Promoters 61.40%
Institutions 20.84%
Non-Institutions 17.76%
Pledged *35.7630.3117.2611.462.462.420.570.570.570.00
* Pledged shares as % of Promoter's holding (%)
Past 10 year's financial track record analysis by Moneyworkds4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is a average quality company.

Data is not available for this company.

Data is not available for this company

Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is an average long term investment. However, you need to ensure you buy at a right price to earn good returns.

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the “Quat Company”. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the “Quat Company”. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year 1995, the company entered into a joint ventured with Schütz & Co, Germany and formed Schütz Dishman Biotech. This company manufactures Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution to cater European market. In 1995-96, the company expanded its activities for the development of many intermediates and APIs. In 1998 in order to penetrate in European and US market, the company formed two wholly-owned subsidiaries Dishman Europe and Dishman USA Inc. In 1998, the company forayed into contract research and manufacture sector. Within a period of 5 years DPCL was able to several contract research and manufacturing projects and later emerged as India’s leading CMO organization (Contract Manufacturing Outsourcing).

Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at Germany, Italy and Turkey.

DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.

Business units:

Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;

Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,

Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.

The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals

 

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback